DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kineret (Anakinra) - Summary



Kineret® (anakinra) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). Kineret® differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus.

Kineret® is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents (see WARNINGS).

See all Kineret indications & dosage >>


Media Articles Related to Kineret (Anakinra)

New Knees in Rheumatoid Arthritis: Cure or Time Machine? (CME/CE)
Source: MedPage Today Rheumatology [2015.07.22]
(MedPage Today) -- Total knee arthroplasty may help RA patients return to a less disabled lifestyle.

How effective is total knee replacement in patients with rheumatoid arthritis?
Source: Arthritis / Rheumatology News From Medical News Today [2015.07.21]
Studies that have assessed the effects of total knee replacement on quality of life are scarce and have been almost exclusively limited to patients with osteoarthritis, even though rheumatoid...

Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Source: MedicineNet Arthritis Specialty [2015.06.25]
Title: Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM

Rheumatoid Arthritis Early Symptoms and Signs
Source: MedicineNet Juvenile Arthritis Specialty [2015.06.17]
Title: Rheumatoid Arthritis Early Symptoms and Signs
Category: Diseases and Conditions
Created: 6/24/2013 12:00:00 AM
Last Editorial Review: 6/17/2015 12:00:00 AM

Positive results from Phase 3 study evaluating Cimzia in DMARD-naïve rheumatoid arthritis patients
Source: Arthritis / Rheumatology News From Medical News Today [2015.06.16]
UCB has announced data that may in the future offer alternative care options for rheumatoid arthritis (RA) patients who have not been treated with disease-modifying anti-rheumatic drugs...

more news >>

Published Studies Related to Kineret (Anakinra)

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). [2014]
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of exercise intolerance due to impaired myocardial relaxation and/or increased stiffness. Patients with HFpEF often show signs of chronic systemic inflammation, and experimental studies have shown that interleukin-1 (IL-1), a key proinflammatory cytokine, impairs myocardial relaxation...

Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. [2011.07]
CONTEXT: Obesity induces low-grade inflammation that may promote the development of insulin resistance. IL-1 is one of the key inflammatory factors. OBJECTIVE: The objective of the study was to demonstrate improvement of insulin sensitivity by blocking IL-1... CONCLUSIONS: Our results suggest that anakinra does not improve insulin sensitivity in obese, insulin-resistant, nondiabetic subjects.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). [2011.05]
OBJECTIVES: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA)... CONCLUSIONS: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number: NCT00339157.

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). [2010.05.15]
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which interleukin-1 (IL-1) plays a central role...

Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. [2009.03.15]
OBJECTIVE: To evaluate the clinical response, safety, and tolerability of a single intraarticular injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee... CONCLUSION: Anakinra was well tolerated as a single 50-mg or 150-mg intraarticular injection in patients with OA of the knee. However, anakinra was not associated with improvements in OA symptoms compared with placebo.

more studies >>

Clinical Trials Related to Kineret (Anakinra)

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria [Completed]
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.

Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms triggered by exposure to cold and variable in expression. Currently there is no standard reliable agent available for the treatment of patients with FCU. This study will evaluate the efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and maintenance therapy in patients with FCU.

Anakinra (Kineret«) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) [Completed]
The purpose of this study is to evaluate the percentage of subjects in Australian clinical practice continuing treatment with Anakinra (Kineret«) at the end of study week 48 in subjects with active RA. The continued use of Kineret« will be based on pre-defined response assessment criteria for subjects with active RA.

Evaluating Kineret« (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire [Completed]
The primary purpose of this study is to assess the ease-of-use of SimpleJectTM compared to pre-filled syringe(s) when using Kineret« in RA subjects. The secondary purpose of this study is to assess the level of fear and anxiety associated with the use of both injection methods, to assess safety when using SimpleJectTM and to evaluate the Ease-of-Administration Questionnaire (EAQ) in terms of the quality of items, item performance, and the instrument reliability.

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis [Recruiting]

- Severe atopic dermatitis, also known as eczema, is a chronic inflammatory skin

condition that affects both children and adults and causes severe itching and skin redness. Current treatments of atopic dermatitis include topical creams and lotions, light therapy, and medications. However, the difficulty with long-term treatment for the chronic and severe nature of the disease requires more effective and better-tolerated therapeutic options.

- Anakinra is a drug that blocks a substance called interleukin-1 (IL-1), which may be

important in causing the inflammation in atopic dermatitis. Researchers are interested in determining whether anakinra can be used to help treat atopic dermatitis. Anakinra has been approved by the Food and Drug Administration to treat rheumatoid arthritis in adults and children, but it has not been approved for use in adults or children with atopic dermatitis and is considered an experimental treatment in this study. In this study Anakinra will be administered as an injection under the skin every day for 3 months


- To assess the safety and effectiveness of using anakinra to treat severe atopic dermatitis

in children.


- Children between 10 and 18 years of age who have been diagnosed with severe atopic

dermatitis that has not responded to standard treatment.


- Initial Screening: Participants will have an initial screening visit with a complete

physical examination and medical history, blood and urine tests, photographs of the skin ,skin biopsy, and other tests as required.

- Run-in Period: At the screening visit, participants will receive a diary card and will

be asked to track their atopic dermatitis symptoms on standard treatment for 2 months.

- Start of Treatment: At the end of the 2 month Run-in period participants will return

for an inpatient visit (2 days) to receive the initial dose of anakinra and will be watched for any side effects. During the inpatient visit, participants will have additional examinations and blood and urine tests, and will be instructed on how to administer the anakinra injections at home.

Treatment Period: - Participants will return once a week for the first 2 weeks of treatment,

at the end of the first month, and then once a month for the following 2 months, for a physical exam and blood tests. Participants will be asked to record symptoms related to their atopic dermatitis, anakinra administration and any side effects related to the anakinra on the diary card. The diary cards will be reviewed and collected at each visit.-

End of Treatment Period: At the end of 3 months of treatment with anakinra, participants will again be asked to record symptoms related to their atopic dermatitis on the diary card. Participants will be seen once a month for 3 months for a physical exam, blood tests and review of the diary card. . The final study visit will take place at the end of the 3rd month and will include a physical exam, blood tests, photographs and skin biopsy.

Anakinra in Hidradenitis Suppurativa [Recruiting]
Aim of this double-blind, randomized, controlled clinical trial is to compare the safety and the efficacy of anakinra over placebo for the management of patients with hidradenitis suppurativa (HS) of Hurley II and Hurley III disease stage. Patients will be evaluated on subsequent follow-up visits. Two scores will be applied: disease activity as assessed in the protocol by the investigator; and Sartorius score. Primary efficacy endpoint will be the comparisons of visual analogue scores, of disease activity, of Sartorius score and of dermatology life quality index between the two groups of treatment over follow-up.

more trials >>

Reports of Suspected Kineret (Anakinra) Side Effects

Pyrexia (8)Alanine Aminotransferase Increased (6)Rash (6)Dyspnoea (4)Vomiting (4)Cytolytic Hepatitis (4)Aspartate Aminotransferase Increased (4)Leukopenia (4)Liver Injury (3)Drug Ineffective (3)more >>

Page last updated: 2015-07-22

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015